Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab + tremelimumab, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CONDOR
Crossref DOI link: https://doi.org/10.1186/2051-1426-3-S2-P152
Published Online: 2015-11-04
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Gilbert, Jill
Le Tourneau, Christophe
Mehanna, Hisham
Fayette, Jerome
Goswami, Trishna
Emeribe, Ugochi
Jarkowski, Anthony
Melillo, Giovanni
Siu, Lilian L
Article History
First Online: 4 November 2015